<DOC>
	<DOC>NCT00523679</DOC>
	<brief_summary>The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.</brief_summary>
	<brief_title>Symbicort SMART (Symbicort Maintenance And Reliever Therapy)</brief_title>
	<detailed_description />
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this program. Since this programme intends to describe Symbicort use in routine clinical practice when prescribed as Symbicort maintenance and reliever therapy, there are no programme specific exclusion criteria, other than: involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Symbicort</keyword>
	<keyword>SMART</keyword>
	<keyword>inhaler</keyword>
	<keyword>compliance</keyword>
	<keyword>Naturalistic</keyword>
	<keyword>Observational</keyword>
</DOC>